Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

ASH 2024 Summary: CLL Highlights

2024 ASH Annual Meeting Insights Hub

A. Danilov

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

ASH 2025 Review: Updates in Frontline & R/R DLBCL

University of Colorado Division of Hematology

M. Kamdar

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ASH 2024 Summary: FL Highlights

2024 ASH Annual Meeting Insights Hub

P. Strati

ASH 2025 Review: Acalabrutinib + Venetoclax +/- Obinutuzumab vs. Che…

University of Colorado Division of Hematology

M. Kamdar

Year in Review 2024: CLL Highlights

The University of Kansas Cancer Center

M. Hoffmann

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

ASH 2024 Summary: Clinical Application of Practice-Changing Abstract…

2024 ASH Annual Meeting Insights Hub

K. Rogers, J. Woyach

ASH 2024 Insights: Ph 3 AMPLIFY - Fixed-Duration Acalabrutinib + Ven…

2024 ASH Annual Meeting Insights Hub

J. Brown

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

The Future of CLL Treatment: Combination Therapies, Overcoming Resis…

MyCancerHaven

R. Vij, A. Kittai

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

CLL in 2024: Evolution of the Role of Novel Targeted Therapies

Louisville Hematology Highlights

C. Coombs

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez